By Zaeem Shoaib


Shares of Greenwich LifeSciences rose after the company said it is preparing for filing a biologics license application for its experimental breast cancer immunotherapy GLSI-100 with the U.S. Food and Drug Administration.

The Stafford, Texas.-based biopharmaceutical company's shares were up more than 5.7% to $8.79 in recent trading. The stock is down almost 48% in the last 12 months.

Greenwich LifeSciences is currently studying GLSI-100 in phase 3 trials in the U.S. and Europe for the prevention of recurrences in certain breast cancer patients who have previously undergone surgery.

The company said about 30 clinical sites in the U.S. are currently recruiting patients and it expects to add 10 sites in 2024, bringing the total sites in the U.S. to about 35 to 40 sites.

Greenwich LifeSciences said it also has contracts in place to add up to an additional 105 to 120 sites in Europe subject to regulatory approval, which is expected in 2024.


Write to Zaeem Shoaib at zaeem.shoaib@wsj.com


(END) Dow Jones Newswires

02-14-24 1015ET